Evidence map›Paper›PMID 34679113›Full record

Observational studyPloS one2021

Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study).

Shinkichi Takamori, Taro Ohba, Mototsugu Shimokawa, Taichi Matsubara, Naoki Haratake, Naoko Miura, Ryo Toyozawa, Masafumi Yamaguchi, Takashi Seto, Mitsuhiro Takenoyama

Open access · goldAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Shinkichi TakamoriDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan.ORCID 0000-0001-8175-6798
Taro OhbaDepartment of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Maidashi, Higashi-ku, Fukuoka, Japan.
Mototsugu ShimokawaDepartment of Biostatistics, Yamaguchi University Graduate School of Medicine, Minamiogushi, Ube-shi, Yamaguchi, Japan.
Taichi MatsubaraDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan.
Naoki HaratakeDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan.
Naoko MiuraDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan.
Ryo ToyozawaDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan.
Masafumi YamaguchiDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan.
Takashi SetoDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan.
Mitsuhiro TakenoyamaDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Notame, Minami-ku, Fukuoka, Japan.
National Hospital Organization Kyushu Cancer Center · JPKyushu University · JPYamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) have markedly improved the prognosis of many patients with advanced non-small cell lung cancer (NSCLC). However, the relationship between the patient's nutritional/immunologic status and the outcomes of ICI treatment remains unclear. In previous retrospective studies, we reported that the controlling nutritional status (CONUT) score, skeletal muscle area, and neutrophil-to-lymphocyte ratio were independent predictors of the response of NSCLC patients to anti-PD-1 drugs. The aim of this prospective multi-center study is to investigate the clinical impact of pre-treatment nutritional/immunologic indices and early post-treatment changes in the indices on treatment outcomes in advanced NSCLC. The main inclusion criteria are: (1) stage IV NSCLC, or stage III NSCLC not applicable for definitive chemoradiotherapy; (2) treatment with ICIs (monotherapy or combined with chemotherapy) as first-line therapy; and (3) available data on PD-L1 expression on tumor cells. A total of 300 patients will be enrolled prospectively. Enrollment will begin in 2020 and the final analyses will be completed by 2025.

Indexed as

AlbuminsB7-H1 AntigenBiomarkersCarcinoma, Non-Small-Cell LungCholesterolHumansImmune Checkpoint InhibitorsLung NeoplasmsLymphocyte CountMaleNeoplasm StagingNutritional StatusPrognosisProspective StudiesTreatment OutcomeAlbuminsB7-H1 AntigenBiomarkersCD274 protein, humanCholesterolImmune Checkpoint Inhibitors

Identifiers

PMID34679113
PMCPMC8535181
OpenAlexW3206104384

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.